LivaNova plc Stock
LivaNova plc Stock
The price for the LivaNova plc stock decreased slightly today. Compared to yesterday there is a change of -€0.500 (-0.680%).
With 13 Buy predictions and not the single Sell prediction the community is currently very high on LivaNova plc.
However, we have a potential of -7.48% for LivaNova plc as the target price of 68 € is below the current price of 73.5 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for LivaNova plc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of LivaNova plc in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of LivaNova plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| LivaNova plc | -0.680% | 5.000% | 0.000% | 100.820% | 40.000% | 45.545% | 4.255% |
| Haemonetics Corp. | 5.520% | 1.370% | 12.121% | - | 8.029% | - | - |
| Bio-Rad Labs Inc. A | 2.020% | 6.718% | 18.955% | 34.066% | 18.263% | -16.393% | -52.713% |
| Penumbra Inc | -0.070% | 0.795% | 0.432% | 36.364% | 4.730% | 22.368% | 23.670% |
Comments
LivaNova (LIVN) had its price target raised by Needham & Company LLC from $81.00 to $93.00. They now have a "buy" rating on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
LivaNova (LIVN) had its "overweight" rating reaffirmed by KeyCorp. They now have a $92.00 price target on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
LivaNova (LIVN) had its price target lowered by Robert W. Baird from $78.00 to $76.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
News
LivaNova Q2 Earnings Call Highlights
Key Points
- Interested in LivaNova PLC? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 9.8% year over year on a constant-currency basis to $391 million, while adjusted
